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Abstract
Introduction: Acute lymphocytic leukemia is one of the most common type of cancer in 
children and it is characterized by excessive and disordered immature leukocytes in the 
bone marrow.
Objectives: Identify  oral  and  general  common  signs  and  symptoms  of  Acute 
lymphocytic  leukemia  in  pediatric  patients  and  when  receiving  chemotherapy, 
hematopoietic cell transplantation, and/or radiation therapy.
Methods:  A systematic  literature search in  PubMed,  Scielo and B-on data  base was 
made, giving preference to articles from the last 10 years and with free access, using the 
following keywords: children, acute lymphoblastic leukemia, treatment, early effects, 
long-term effects, oral health.
Development:  There  are  many  oral  manifestations  in  this  patients  either  from  the 
disease it self or from the treatment. Some of the most common are: bone alterations, 
trismus,  gingival  bleeding,  echymoses,  mucosal  pallor,  mucositis,  xerostomia  and 
oportunistic infections.
Discussion and Conclusion: The dental clinicians may contribute to a higher survival 
rate and improved oral related quality of life in ALL patients since they might enable an 
early  diagnose,  they  are  able  to  support  antineoplastic  treatment  success  and 
monitoring  /  treatment  of  long term changes.  Dentists  shall,  therefore,  be  a  critical 
element of the multidisciplinary team in hematology-oncology context.
Keywords:  children, acute lymphoblastic leukemia, treatment, early effects, long-term 
effects, oral health.
i
Resumo
Introdução:  A leucemia linfocítica aguda é um dos tipos de cancro mais comuns em 
crianças e é caracterizada pela produção excessiva e desordenada de leucócitos imaturos 
na medula óssea.
Objetivo:  Identificar sinais, sintomas gerais e orais da leucemia linfocítica aguda em 
crianças, sujeitas a tratamento (quimioterapia, transplante de células hematopóieticas e 
ou radioterapia). Identificar o potencial contributo do médico dentista quer na sobrevida 
quer na qualidade de vida relacionada com a saúde oral destes pacientes.
Metodologia:  Foi  realizada  uma pesquisa  bibliográfica nas  base  de  dados  PubMed, 
Scielo e B-on, considerados  preferencialmente os artigos publicados nos  últimos 10 
anos e os  artigos de acesso livre; foram utilizadas as palavras-chave: children, acute 
lymphoblastic leukemia, treatment, early effects, long-term effects, and oral health.
Desenvolvimento: São muitas as manifestações orais presentes nestes pacientes, quer 
resultantes da doença quer do tratamento. Algumas das mais comuns são: alterações 
ósseas,  trismus,  sangramento  gengival,  equimoses,  palidez  das  mucosas,  mucosite, 
xerostomia, e infecções oportunistas.
Discussão e Conclusão:  O médico dentista  pode contribuir  para uma maior  taxa de 
sobrevivência  e  melhoria  da  qualidade  de  vida  relacionada  com  a  saúde  oral  dos 
pacientes com ALL uma vez que possibilita um diagnóstico precoce,  apoia o sucesso 
do tratamento antineoplásico e o acompanhamento/tratamento das alterações que podem 
surgir a longo prazo. O médico dentista pode ser assim um elemento crítico da equipa 
multidisciplinar no contexto da hematologia-oncologia.
Palavras-chave: crianças, leucemia linfocítica aguda, tratamento, efeitos a curto prazo, 
efeitos a longo prazo, saúde oral.
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Oral Considerations in Pediatric Patients with Acute Lynphoblastic Leukemia
I. Introduction
Leukemia constitutes approximately 30% of all childhood cancers (Padmini and Bai, 
2014;  Cho,  Cheng  &  Cheng,  2000;  Francisconi  et  al,  2016).  Acute  lymphoblastic 
leukemia (ALL) is the most common type of malignancy encountered in children and 
accounts  for  about  75%  of  childhood  leukemia’s  (Javed  et  al., 2012).  ALL is  a 
malignant disorder resulting from the clonal proliferation of lymphoid precursors with 
arrested maturation giving rise  to B-cell or T-cell  leukemias or sometimes to mixed 
lineage leukemia (Padmini and Bai, 2014).
The cause of leukemia is unknown although certain leucogenic factors are postulated, 
including ionizing radiation, genetic and immunological factors, viruses and exposure to  
benzene derivatives and ethyl carbonates (Xavier and Hegde, 2010).
Oral complications can compromise the protocols of chemotherapy, often leading to 
decrease of the administered dose, change in treatment protocol, or even discontinuation 
of antineoplastic therapy, directly affecting patient survival (Zimmermann et al., 2015).
Chemotherapy and/or  radiotherapy for  the  treatment  of  cancer  or  in  preparation  for 
hematopoietic  cell  transplantation (HCT) may cause many acute  and long-term side 
effects in the oral cavity. Furthermore, because of the immunosuppression that patients 
experience, any existing or potential sources of oral/dental infections and/or soft tissue 
trauma can  compromise  the  medical  treatment,  leading  to  morbidity,  mortality,  and 
higher hospitalization costs (American Academy of Pediatric Dentistry, 2013).
Objectives
Identify oral and general common signs and symptoms of Acute lymphocytic leukemia 
in  pediatric  patients and  when  receiving  chemotherapy,  hematopoietic  cell 
transplantation, and/or radiation therapy.
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I.1. Materials and methods
 A systematic literature search in PubMed, Scielo and B-on data base was made, giving 
preference to articles from the last 10 years and with free access, using the following 
keywords: children, acute lymphoblastic leukemia, treatment, early effects, long-term 
effects, and oral health.
Manuscript analysis was substantiated on Meta-Analysis Reporting Standards (Module 
A1 and Module A2, APA style).
II. Development
II.1. Signs and symptoms of Acute Lymphoblastic Leukemia
Signs of leukemia often manifest in the mouth, and patients usually search for dental 
care  thinking  that  diseases  is  of  local  origin.  It  is  worth  to  note  that  dentists  are 
responsible for initiating the diagnosis in 33% of patients with acute myelomonocytic 
leukemia (Stafford et al.,  1980). These manifestations should be recognizable, leading 
to a fully investigation with additional tests  or referring the patient  to  a specialized 
professional in order to reach an early diagnosis (Francisconi et al., 2016).
II.1.1. Common signs and symptoms
Early symptoms,  including nonspecific  ones,  such as fatigue,  dyspnea,  fever,  pallor, 
weight loss or bleeding, may be associated with pancytopenia (anemia, neutropenia or 
thrombocytopenia).  Blasts  may  also  infiltrate  organs  or  lymph  nodes,  resulting  in 
hepatosplenomegaly, lymphadenopathy or bone pain. Symptoms of testicular or central 
nervous system (CNS) involvement are rarely noted at  diagnosis (Francisconi  et al., 
2016).
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II.1.2. Oral manifestations
Oral  complications  occur  frequently  and  may  point  out  the  initial  evidence  of  the 
disease or of its relapse. Oral lesions arise in both acute and chronic forms of all types 
of leukemia. However, they are far more frequent in acute stages (Francisconi  et al., 
2016).  These  oral  manifestations  either  may  be  the  result  of  direct  infiltration  of 
leukemic cells (primary) or secondary to underlying thrombocytopenia, neutropenia, or 
impaired granulocyte function (Francisconi et al., 2016).
Gingival  bleeding,  hyperplasia,  opportunistic  infections  and  bone  alterations  are 
common  oral  manifestations  of  leukemia.  Leukemic  infiltration  can  cause  gingival 
swelling which is a constant finding of the disease. The gingival hyperplasia is usually 
generalized and differs in severity (Lowal et al., 2015).
Some authors describe gingival swelling as frequent manifestation of ALL (Pai  et al., 
2012; Silva et al., 2012; Lim and Kim., 2014).
Katz and Peretz (2002) reported trismus as the first presentation of ALL in a 6-year-old 
boy, when intraoral examination and panoramic radiograph demonstrated no signs of 
infection  and/or  other  pathology.  The  trismus  could  be  explained  as  an  intensive 
infiltration of leukemic cells into the deep portion of the muscles of mastication (Katz 
and Peretz, 2002, Francisconi et al., 2016).
ALL may also involve the lymphoid-bearing tissue of the orofacial region including the 
tonsils. Lymphadenopathy of the head and neck region is a consistent sign (Declerck 
and Vinckier, 1988). (Francisconi et al., 2016)
Intraorally, mucosal pallor, or echymoses also may be noted (Declerck and Vinckier, 
1998)  and petechia as well (Francisconi et al., 2016).
Another possible manifestations can be sore throat, laryngeal pain, and oral ulceration 
(Padmini and Bai, 2014; da Fonseca, 2004).
Several  studies  have  reported  an  increased  incidence  of  mucosal  anomalies 
characterized by extensive ulcers, and oral mucosal infections (mucositis, candidiasis, 
herpes simplex) in ALL patients (Anirudhan et al., 2008).
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Pericoronitis may also correspond to an initial manifestation of ALL (Aronovich and 
Connolly, 2008).
II. 2. Treatment of Acute Lymphoblastic Leukemia
Once diagnosed,  treatment  is  carried  in  distinct  phases.  The  purpose  is  to  induce a 
remission and maintain this with appropriate supportive care such as the management of 
anemia, bleeding and infection. Treatment also involves the eradication of malignant 
cells from extra-medullary sites, such as the central nervous system, and the testes in 
boys (Xavier and Hegde, 2010).
The treatment of leukemia depends on factors such as type and subtype of the disease, 
risk factors, and age. In general, the recommended treatment is chemotherapy with or 
without  adjuvant  treatments.  Hematopoietic  stem  cell  transplantation  (HSCT)  is 
generally  performed  in  the  acute  forms  of  the  disease  and  some  cases  of  chronic 
myeloid leukemia (Zimmermann et al., 2015).
The treatment of ALL is based on clinical risk and is usually divided in four phases 
(Padmini and Bai, 2014; Xavier and Hegde, 2010; da Fonseca, 2004; Barbería  et al., 
2008):
Remission induction - generally lasts 28 days and consists in a combination of 3 or 4 
drugs  (cytostatics  and  imunosupressants  –  the  most  commonly  used  are  vincristine, 
prednisone,  and  L-asparaginase)  A 95%  success  rate  is  frequently  achieved.  The 
remission is a known pre-requisite for prolonged survival.
CNS preventive therapy/prophylaxis - CNS can act as a sanctuary site for leukemic 
infiltrates  because  systemically  administered chemotherapeutic  drugs are  not  able  to 
cross the blood-brain barrier. Cranial irradiation and/or weekly intrathecal injection of a 
chemotherapeutic agent (usually methotrexate) are used. This presymptomatic treatment 
can be done in each phase as well.
Consolidation or intensification - in an attempt to kill any remaining leukemic cells, it is 
designed  to  minimize  the  development  of  drug  cross-resistance  through  intensified 
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treatment.  Commonly  used  drugs  include:  imunosupressants,  antimetabolites  and 
alkylating agents (eg. 6-mecaptopurine, cytarabine and cyclophospamide). This phase 
lasts for 4 weeks.
Maintenance  -  The  purpose  is  to  suppress  leukemic  growth  through  continuous 
administration of cytotoxic drugs (namely methotrexate and 6- mercaptopurine). The 
optimal length of this phase has not been established yet but usually lasts from 2.5 to 3 
years.
II. 3. Post-treatment oral effects
The oral mucosa is highly susceptible to the effects of chemotherapy and radiotherapy 
due high mitotic activity and is the most frequently documented source of sepsis in the 
immunosuppressed pediatric leukemic patients. Existing lesions that might normally lie 
dormant can flare up and become life threatening once the child is immune suppressed 
(Padmini and Bai, 2014).
II. 3.1. Early Oral complications of antineoplastic treatment
Oral complications at this stage often include: mucositis, gingival bleeding, xerostomia 
(Lowal et al., 2015; Padmini and Bai, 2014) opportunistic infections (Zimmermann et  
al., 2015).
Mucosal ulceration is one of the most frequent oral problem encountered (Padmini and 
Bai, 2014;  Harris et al., 2014) and has a significant impact on patients  quality of life 
and treatment plan (Cawley & Benson, 2005; Rubenstein et al).
Figliolia  and  colleagues  (2008)  examined  169  ALL  pediatric  patients  and  the 
association of oral mucositis (OM) with age, gender and leucocyte count were assessed 
(Figliolia  et  al .  2008).  Forty-six  percent  of  patients  developed  OM  during 
chemotherapy. The study also showed that 48% of patients <9 years old and 39% of the 
patients between 10 and 18 years old developed OM . One study  conducted by Pels 
(2012) reported that OM was present prior to anticancer therapy in 5% of a group of 78 
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pediatric patients with ALL. Sixty two percent of these patients manifested OM after the 
induction of chemotherapy with average time of 10-16 days of chemotherapy (Pels, 
2012).
Xerostomia or reduced salivation and dysguesia, is a frequent effect of radiotherapy in 
the  head  and  neck  region.  A variety  of  drugs  other  than  chemotherapeutics  like 
sedatives, opiates, antidepressants, antihistamines, diuretics may also be responsible to 
induce xerostomia. (Gupta, Epstein & Sroussi, 2006).
In a cross sectional study done by Dholam and colleagues (2014) 33 pediatric patient 
(5-15 years old, both gender) undergoing chemotherapy (induction phase particularly) 
were observed and they found that the oral health status, DMFT index and gingival 
findings  were  significantly  deteriorated  following  the  induction  phase.  This  can  be 
explained by the change in quality and quantity of saliva due to anticancer treatment 
(Dholam  et  al.  2014).  Other  study reported  by  Azher  and Shiggaon  (2013)  similar 
results were found (Lowal et al., 2015).
Prolonged bleeding in childhood malignancy may be caused by chemotherapy induced 
myelosuppresion, certain medications and disorders of clotting and platelets related to 
the baseline disease (Xavier and Hegde, 2010).
Fungal infections (Candida) of the oral  mucosa are  common and can cause burning 
sensation, distortion of taste and problems with swallowing. Viral infections especially 
the re-activation of herpes simplex virus type I (HSV-1) is serious because they can 
cause pain and problems with hydration and nutrition (Xavier and Hegde, 2010).
The leukemic child may be at high risk for dental caries from a dietary standpoint for a 
number  of  reasons  as  patients  are  prescribed  daily  nutritional  supplements  rich  in 
carbohydrate to maintain or gain weight and oral  pediatric medications contain high 
amounts of sucrose (e.g., nystatin) which makes them prone for dental caries. (Padmini 
and Bai, 2014).
Some patients  may complain  of  paresthesias  caused  by  leukemic  infiltration  of  the 
peripheral nerves. Others may report dental pain mimicking irreversible pulpitis in the 
absence of a dental/periodontal infection. (da Fonseca, 2004)
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Oral complications of treatment of leukemia in children such as; leukemic infiltration in 
the mandible, trismus, mucormycosis and oral aspergillosis could be found (Lowal  et  
al., 2015).
For pediatric patients  who are undergoing bone marrow transplant and radiotherapy, 
they  may  develop  graft-versus-host  disease  (GVHD)  2-3  weeks  after  the 
transplantation , and it's induced by the cytotoxic effect of the donor T lymphocytes in 
the receiver tissues. Those patients may manifest oral signs such as: erythema, erosion, 
ulceration of the mucosa, lichenoid changes and xerostomia. (Lowal et al., 2015)
II. 3.2. Late and long term effects of antineoplastic treatment
The most common changes are microdontia, agenesis of teeth, change in crown or root 
shape,  defective  mineralization  of  the  dental  structure,  and  delayed  tooth  eruption 
(Padmini and Bai, 2014).
Direct radiation of the jaw, face and head can promote the most serious side effects in 
children  which  includes  incomplete  development  of  the  jaws,  arrested  tooth 
development which can cause small teeth, atrophy of the overlying soft tissue; enamel 
malformation and incomplete calcification of teeth (Xavier and Hegde, 2010).
Some cross-sectional studies correlate ALL treatments and dental anomalies frequency 
(Minicucci,  Lopes  &  Crocci,  2003;  Maciel  et  al.,  2009;  Khojastepour,  Zareifar  & 
Ebrahimi, 2014). The clinical and radiographic examination showed that 82%, 80% and 
28% of  the  same  patients  had  at  least  one  dental  anomaly,  respectively.  Moreover, 
Maciel  et al.  2009 reported that agenesis, microdontia, tapering roots and short roots 
was considerably greater on the same group Vasconcelos  et al.  2009 stated that ALL 
treatment does affect the dental age maturity of the involved patients compared to their 
healthy counterparts. (Vasconcelos et al., 2009; Lowal et al., 2015)
A study conducted by Sonis et al. in 97 children to evaluate craniofacial development in 
long term survivors of acute lymphoblastic leukemia found that craniofacial effects of 
therapy were observed in only those children who received 2400 cGy before 5 years of 
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age. Ninety percent of children in this group had diminished mandibular growth that 
was determined by cephalometric analysis (Padmini and Bai, 2014).
Another similar study conducted by Guyuron et al., has shown that among 41 patients 
who received irradiation to the head and face during growth thirty-eight of them had 
soft tissue or bony deformities. (Padmini and Bai, 2014). A study done by Minicucci 
and  colleagues  (2003)  showed  delays  in  dental  development,  hypoplasia,  and 
microdontia  in children receiving chemotherapy. (Minicucci,  Lopes & Crocci,  2003; 
Padmini and Bai, 2014).
Some  studies  also  refer  the risk  of  developing  of  mucoepidermoid  carcinoma  in 
previously treated leukemic children (Boccon et al., 2005; Sandoval and Jaybose, 2001; 
Cheuk et al., 2008) and squamous cell carcinoma secondary to allogenic bone marrow 
transplant. (Lowal et al., 2015).
Children undergoing an allogenic bone marrow transplant (BMT) often develop Graft-
versus-Host-Disease (GVHD) and oral  cavity  may be  the first  or  only site  showing 
GVHD. An increasing level of xerostomia and/or generalized stomatitis which appear 
hundred or more days after the BMT are indicators of chronic GVHD. The younger the 
child, the greater is the risk for craniofacial and developmental abnormalities (Xavier 
and Hegde, 2010).
III. Discussion
Despite the increased incidence of neoplastic malignancies, a higher survival has been 
reported  -  early  diagnosis  and  improved  treatments  share  important  contributions 
(Barbosa  et al., 2010;  Silva  et al., 2012; Lim &Kim., 2014) . ALL is associated with 
general and common signs and symptoms with frequent oral expression (Francisconi et  
al., 2016; Stafford et al., 1980). A depth knowledge and careful attention to such signs 
and symptoms allow the dental clinician to contribute for an early diagnosis, improving 
survival.
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Oral mucosa is highly susceptible to the effects of chemotherapy and radiotherapy and it  
is a frequent source of sepsis in the treatment phase - lesions that might normally lie 
dormant  can  flare  up.  Such  oral  complications  often  compromise  chemotherapy 
protocols, leading to a decreased dose administration, changes in the protocol treatment, 
or even discontinuation of antineoplastic therapy – these changes affect directly both 
patient survival and its quality of live (Padmini and Bai, 2014; Zimmermann  et al., 
2015).  Dental  professionals  should  be  able  to  promote  adequate  oral  care  during 
treatment, in order to prevent its compromise, and thus, contribute to both survival and 
quality of live related to oral health.
Several studies support the reduction of the amount of microbial flora, reduction pain 
and bleeding,  and prevention infection and reduces the  risk of  dental  complications 
provided by oral care (Cawley & Benson, 2005; Rubenstein et al, 2004). OM is one of 
the most frequent complications and it can be highly severe and aggressive. Harris and 
colleagues (2008) reported an evidence-based intervention consisting on adherence to a 
oral care regimen can reduce the duration and severity of OM, although oral care has 
not been demonstrated to completely prevent OM, (Harris  et al, 2008). Furthermore, 
Cheng  and  colleagues  (2001)  found  a  38% decrease  in  OM  incidence  in  children 
supervised  with  oral  care  when  compared  to  a  control  group  (without  oral  care 
supervision). Moreover, both pain and OM severities were also significantly reduced 
(Cheng,  Molassiotis,  Chang,  Wai,  & Cheung,  2001;  Cheng,  Chang,  & Yuen, 2004). 
These results reinforced the importance of oral care in ALL children along treatment.
Leukemia  treatment  may  exert  an  adverse  influence  on  odontogenesis  and  growth 
centers,  affecting  maturation  of  craniofacial  complex  and  resulting  in  asymmetrical 
facial growth and malocclusion (Padmini and Bai, 2014). There is also risk involving 
the development of mucoepidermoid carcinoma in leukemic patients and a  squamous 
cell carcinoma secondary to allogenic bone marrow transplant as reported by (Lowal et  
al., 2015). These abnormalities may have a significant impact on aesthetic and may also 
cause functional and occlusal disturbances A relapse of ALL is also possible, associated 
with and again, oral manifestations. The long-term monitoring of these patients, by the 
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dentist,  allows an earlier  detection and therefore an earlier  treatment/management of 
such anomalies.
IV. Conclusions
The dental clinician should be aware and capable to recognize the general and oral signs 
and symptoms of  ALL,  contributing  to  an  early  diagnosis,  and  therefore,  to  higher 
survival rate.
During antineoplastic treatment, dentists should be able to provide adequate and proper 
oral care to patients, in order to prevent and minimize the oral complications associated 
to treatment - minimizing the possibility of treatment compromising - improving the 
general and oral quality of life of the patient, contributing to a higher success of the 
antineoplastic treatment and again, to a higher survival rate.
After  treatment,  the  dentist  should  provide  a  long-term  follow-up,  treating  and 
managing all the manifestations that can appear. Relapse of the disease should also be 
considered. It is of great importance that caregivers advise and guide the patients for a 
good oral hygiene and oral care.
The dental clinicians may contribute to a higher survival rate and improved oral related 
quality  of  life  in  ALL patients  since  they  might  enable  an  early  diagnose,  support 
antineoplastic treatment success and monitoring treatment of long-term effects. Dentists 
shall,  therefore,  be  a  critical  element  of  the  multidisciplinary  team in  hematology-
oncology context.
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